Octanine (Human Coagulation Factor Ix)

Human Coagulation Factor IX, the active ingredient in Octanine, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use. It replaces deficient factor IX in patients with hemophilia B, helping to control bleeding episodes. GNH USA supplies Octanine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Octanine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Octanine is used in the management of inherited bleeding disorders that involve factor IX deficiency. It is indicated for: - Hemophilia B: Provides temporary replacement of factor IX to prevent or control bleeding. - Perioperative management: Supplies factor IX to maintain hemostasis during surgery or invasive procedures. - Trauma‑related bleeding: Restores factor IX levels to achieve hemostasis in acute bleeding events. - Congenital factor IX deficiency (non‑hemophilic): Supplements low endogenous factor IX levels. - Acquired inhibitor‑related bleeding: Bypasses inhibitors to re‑establish clotting function. - Prophylactic therapy: Regular infusions to reduce the frequency of spontaneous bleeds.

Adverse reactions to Octanine may vary in frequency and severity.

Common Side Effects: - Headache - Fever - Nausea - Mild infusion site erythema - Transient increase in liver enzymes - Fatigue

Serious or Rare Side Effects: - Anaphylactic reaction - Development of neutralizing antibodies (inhibitors) - Thromboembolic events - Severe hypersensitivity - Acute hemolysis - Renal impairment

Octanine should be used under careful clinical supervision, with attention to individual patient risk factors.

- Dosing individualisation: Adjust dose based on factor IX activity levels and clinical response. - Monitoring: Regular laboratory assessment of factor IX activity and inhibitor screening. - Infection risk: Observe for signs of viral transmission despite viral inactivation steps. - Pregnancy and lactation: Use only if clearly indicated and benefits outweigh risks. - Pediatric use: Dose adjustments may be required for children. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanine may interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid): - Activated pro‑thrombin complex concentrates (aPCC): May increase risk of thrombosis. - High‑dose factor VIIa: Combined use can lead to excessive clot formation.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid): May enhance clot stability, requiring dose adjustment. - Immunosuppressive agents: Potential impact on inhibitor development. - Vaccines: Monitor for altered immune response. - Antibiotics with renal clearance: May affect factor IX clearance. - Concomitant anticoagulants: May counteract therapeutic effect of Octanine.